Lansdale, PA (PRWEB) November 10, 2010
JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today that it has been awarded an IRS Qualifying Therapeutic Discovery Project (QTDP) grant of approximate $245,000. This grant targeting therapeutic discovery projects that show potential to result in improved therapies to treat areas of unmet medical need or treat chronic or acute diseases and conditions, was awarded to JDP Therapeutics to help fund further clinical trials of JDP-205, an acute care hospital product candidate under development for the treatment of allergies.
The QTDP grant is created under the Patient Protection and Affordable Care Act. The Department of Health and Human Services (HHS) designates such projects based on the potential to produce new cost-saving therapies, support jobs, and increase U.S. competitiveness.
“We are pleased that our research efforts and innovations are being rewarded. This grant will help support the clinical development of our new allergy treatment, and further support our drug development portfolio,” commented Jie Du, Ph.D., President and Chief Scientific Officer of JDP Therapeutics.
“We are delighted that the potential advantages of JDP-205 have been recognized through the award of this grant as we continue to advance the development of JDP-205, a novel allergy therapy. We look forward to the day when JDP-205 is approved and patients in need have access to it,” said Josh Tarnoff, CEO of JDP Therapeutics.
JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.
For further information, please call 215-661-8557 or email info (at) jdptherapeutics (dot) com
# # #